Saving money on the PBS: Ranibizumab or bevacizumab for neovascular macular degeneration?

Medical Journal of Australia

Volumn 194, Issue 11, 2011, Pages 567-568

  Harvey, Ken J ^a   Day, Richard O ^b   Campbell, William G ^c   Lipworth, Wendy ^b  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEVACIZUMAB; ORPHAN DRUG; RANIBIZUMAB; ROSUVASTATIN; VASCULOTROPIN A;

AUSTRALIA; BLINDNESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG INDICATION; EDITORIAL; EXUDATIVE MACULAR DEGENERATION; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; OFF LABEL DRUG USE; PHARMACEUTICS; RETINA MACULA AGE RELATED DEGENERATION; UNSPECIFIED SIDE EFFECT;

EID: 79958830007     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb03105.x     Document Type: Editorial

References (11)

1. Roxon N. Opening address to Consumers Health Forum PBS Summit, 29 Apr 2011. http://www.hirc.health.gov.au/internet/ministers/publishing. nsf/Content/F2D512F124949662CA257881001FC9AD/$File/ nrsp290411.pdf (accessed May 2011).
2. Taylor HR, Keeffe JE, Vu HT, et al. Vision loss in Australia. Med J Aust 2005; 182: 565-568.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
5. Fong DS, Custis P, Howes J, et al. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 2010; 117: 298-302.
6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
7. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.
8. Australian Government Department of Health and Ageing. National Medicines Policy. 2000. Canberra: Commonwealth of Australia, 1999.
9. Australian Government. National Strategy for Quality Use of Medicines. Canberra: Commonwealth of Australia, 2002.
10. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 28 Apr [Epub ahead of print].
11. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian regulatory guidelines for prescription medicines. Canberra: Commonwealth of Australia, 2004. http:// www.tga.gov.au/pdf/pm-argpm.pdf (accessed May 2011).